Author: Richa Madurkar, PharmD, BCOP, Senior Clinical Oncology Pharmacist, OncoHealth Until recently, standard first-line treatment options for CLL included indefinite therapy with a covalent BTK inhibitor (cBTKi) such as ibrutinib, acalabrutinib, or zanubrutinib ±...
Author: Corey Wise, RPh, M.S., BCOP, Senior Clinical Oncology Pharmacist, OncoHealth Health insurance premiums are projected to see their largest increase in 15 years — and rising cancer rates among working-age adults are partly to blame. Here’s how prevention and...
Why Nutrition Deserves More Attention from Health Plans Malnutrition in cancer care is more than a clinical issue; it’s a financial one. According to the National Cancer Institute, 30% to 85% of people with cancer do not get enough nutrients or calories to support...
When we talk about “toxicity” in cancer care, most think of the physical side effects of treatment. But there’s another form that can be just as devastating: financial toxicity. Research shows the scope of this burden[1]: 42% of patients with cancer report significant...
